Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Ainos, Inc. (NASDAQ:AIMDGet Free Report) was the target of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 113,000 shares, a decrease of 21.1% from the October 31st total of 143,300 shares. Approximately 4.5% of the company’s shares are sold short. Based on an average daily trading volume, of 351,500 shares, the short-interest ratio is currently 0.3 days.

Ainos Stock Down 1.7 %

AIMD stock opened at $0.47 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.33 and a current ratio of 1.37. The business has a fifty day simple moving average of $0.49 and a 200-day simple moving average of $0.66. Ainos has a 52 week low of $0.40 and a 52 week high of $4.29.

Ainos (NASDAQ:AIMDGet Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter. Ainos had a negative net margin of 15,348.14% and a negative return on equity of 75.16%.

About Ainos

(Get Free Report)

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.

Featured Articles

Receive News & Ratings for Ainos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ainos and related companies with MarketBeat.com's FREE daily email newsletter.